Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts from the ‘Bladder’ category

One of the recent trends at cancer conferences that I have noticed has been the creative use of social media by some cancer and urology Society organizations such as AACR, ASCO, AUA and ASH to promote their events and communicate with attendees before, during and after conferences.   It’s not all American organisations either, with some European societies also becoming increasingly digitally aware, including ESMO, EAU and EHA all gradually building an online presence beyond their websites.


Today it’s Friday 13th and we’re heading off on the road again, this time to Washington DC for the much anticipated annual meeting of the American Urology Association (AUA).

We’ll be covering the hot topics on urologic cancers, including bladder and prostate cancers and renal cell carcinoma (RCC). I’m particularly interested in castrate resistant prostate cancer and updates on the abiraterone (Zytiga) data following the recent approval post chemotherapy in the US, and also the long term data for Medivation/Astellas’ MDV3100 from their phase I/II trial. It’s always important to know how patients in the early trials are doing.

error: Content is protected !!